No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
SNDX240621P22500
- 3.33
- +1.44+76.19%
15min DelayClose Jun 20 16:00 ET
3.33High3.33Low
3.33Open1.89Pre Close1 Volume26 Open Interest22.50Strike Price333.00Turnover219.89%IV0.52%PremiumJun 21, 2024Expiry Date3.23Intrinsic Value100Multiplier1DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type-0.8729Delta0.0842Gamma5.71Leverage Ratio-0.1443Theta-0.0006Rho-4.98Eff Leverage0.0023Vega
Intraday
- 5D
- Daily
News
Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although software-as-a-service business Salesforce.com
Syndax Pharmaceuticals(SNDX.US) Officer Buys US$25,037.25 in Common Stock
$Syndax Pharmaceuticals(SNDX.US)$ Officer Goldan Keith A. purchased 1,250 shares of common stock on Jun 14, 2024 at an average price of $20.0298 for a total value of $25,037.25.Source: Announcement Wh
Express News | Syndax Pharmaceuticals Inc: 52% Crc (14 of 27 Pts) Observed in Augment-102 Trial
Express News | Syndax Pharmaceuticals Inc: 96% Crc (23 of 24 Pts) Observed in Beat Aml Trial
Express News | Syndax Pharmaceuticals Inc: Plans to Initiate a Pivotal Trial With This Combination in Front-Line Newly Diagnosed Patients by Year-End 2024
Express News | Syndax Presents Updated Positive Data From Beat Aml and Augment-102 Phase 1/2 Combination Trials of Revumenib in Patients With Acute Leukemias at Eha 2024 Congress
Comments
$Syndax Pharmaceuticals(SNDX.US$ Syndax Pharmaceuticals Says FDA Grants Priority Review to New Drug Application for Acute Leukemia Treatment
MT Newswires· 1 min ago
Syndax Pharmaceuticals (SNDX) said late Tuesday the US Food and Drug Administration has granted priority review for the company's new drug application for revumenib to treat relapsed or refractory acute leukemia, a type of cancer.
The company said the filing was assigned a prescription drug user fee act target action date of S...
MT Newswires· 1 min ago
Syndax Pharmaceuticals (SNDX) said late Tuesday the US Food and Drug Administration has granted priority review for the company's new drug application for revumenib to treat relapsed or refractory acute leukemia, a type of cancer.
The company said the filing was assigned a prescription drug user fee act target action date of S...
Syndax Pharmaceuticals' excess liquidity indicates a cautious approach to debt, but its lack of significant operating revenue and EBIT loss over the last year are worrying. The company's balance sheet appears liquid, but the absence of regular free cash flow generation is concerning.
$Syndax Pharmaceuticals(SNDX.US$ Syndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program
3 MINUTES AGO, 7:00 AM EDT
VIA PR NEWSWIRE
3 MINUTES AGO, 7:00 AM EDT
VIA PR NEWSWIRE
$Syndax Pharmaceuticals(SNDX.US$ See a lot of potential here? with price action after trial PR, its like everyone read ( trial stopped early ) but didn’t read any further? it was stopped for efficacy, it showed improvement and are moving on to next phase!
Read more